Joint pain, tendon injuries, cartilage damage, and other musculoskeletal problems do not always have a simple solution. Medication may control symptoms without addressing the injured tissue, while surgery may be more treatment than some patients need at a particular stage. That gap has increased interest in regenerative orthopedic medicine, also commonly discussed under the broader term orthobiologics.
Regenerative orthopedic medicine uses biological materials, often obtained from a patient’s own body, with the goal of supporting the body’s existing healing response. Examples include platelet-rich plasma, commonly called PRP, and certain bone marrow based preparations. These approaches are being studied and used in selected orthopedic settings, but they are not interchangeable and their evidence varies considerably.
Just as important, “regenerative” does not mean a treatment can automatically regrow worn cartilage, restore a damaged joint to its original condition, or eliminate the need for surgery. Understanding what these treatments actually do makes it much easier to separate reasonable medical use from unrealistic claims.
Regenerative Orthopedic Medicine in Plain Language
Regenerative orthopedic medicine is an area of musculoskeletal care that uses biological materials to influence healing, inflammation, tissue signaling, or recovery in injured or degenerative areas. It may involve blood-derived products such as PRP, bone marrow based preparations, or other orthobiologic materials used during nonsurgical or surgical care.
The basic idea is different from simply masking pain. Instead of focusing only on the sensation of pain, clinicians may use biologic materials to interact with the environment around an injured tendon, ligament, joint, cartilage surface, muscle, or bone.
That sounds straightforward, but the biology is complicated. Different tissues heal at different rates. Some have strong blood supplies, while others receive relatively little blood. Age, injury severity, mechanical stress, joint alignment, activity level, general health, and the exact nature of the damage can all affect the healing process.
Regenerative medicine is not one procedure
One of the most common sources of confusion is treating “regenerative medicine” as the name of a single injection.
It is better understood as a category.
PRP made from a patient’s blood is different from concentrated bone marrow aspirate. Both are different from commercially marketed umbilical cord, amniotic, placental, or exosome products. Their components, regulatory status, risks, evidence, and intended uses may all differ.
Orthobiologics and regenerative orthopedics overlap
Orthopedic specialists often use the term orthobiologics when discussing biological materials used to support musculoskeletal healing. AAOS describes orthobiologics as biological products used with the body’s natural physiology to assist the healing process. They may be used during surgery as well as in nonsurgical treatment.
For patients, the terminology matters less than knowing exactly what substance is being proposed, where it comes from, why it is being used, and what evidence supports its use for the specific diagnosis.
Why Some Orthopedic Problems Are Difficult to Heal
The body already has a repair system. When tissue is injured, chemical signals, blood components, immune cells, growth factors, and repair cells participate in a coordinated response.
The challenge is that not every musculoskeletal structure has the same ability to repair itself.
Blood supply makes a difference
Blood carries many of the components needed for tissue repair. Structures with a strong blood supply may have a different healing capacity from tissues where circulation is limited.
Cartilage is a good example. Articular cartilage, the smooth tissue covering the ends of bones inside a joint, has limited intrinsic healing capacity. Once significant cartilage loss has occurred, the body may not simply replace it with normal articular cartilage.
This is one reason claims that an injection will “regrow an entire joint” deserve careful scrutiny.
Mechanical problems continue after an injection
Biology is only part of orthopedic medicine.
Imagine a patient with persistent knee pain related to osteoarthritis and significant lower limb alignment problems. An injection may influence pain or the local joint environment, but it does not automatically correct abnormal alignment.
The same principle applies to a tendon that remains overloaded because of movement mechanics, training errors, weakness, or occupational stress. Treating the tissue without addressing the forces acting on it may leave an important part of the problem unresolved.
For that reason, regenerative treatment is often considered within a larger plan that can include rehabilitation, activity modification, strength work, weight management when appropriate, bracing, medication, or surgery.
What Does “Regeneration” Actually Mean?
The word regeneration can create expectations that medical science cannot always meet.
In everyday language, regeneration sounds like replacing damaged tissue with brand new tissue. In clinical orthopedics, the goal may be more modest.
Depending on the treatment and condition, physicians may be trying to influence inflammatory signaling, support tissue repair, improve the biological environment around an injury, reduce symptoms, or assist healing after another procedure.
Signaling may matter as much as cell replacement
Stem cell treatments were once commonly described as if injected cells simply arrived at damaged tissue, became new cartilage or tendon cells, and rebuilt the area.
Current understanding is more complicated.
AAOS notes that there is little evidence that injected stem cells simply survive, multiply, and directly create large amounts of healthy replacement tissue. One proposed mechanism involves cellular signaling, in which cells release factors that influence the surrounding biological environment and the body’s own repair processes.
That distinction matters. A biological effect does not automatically mean structural regeneration has occurred.
Symptom improvement and tissue regeneration are not the same outcome
A patient may experience less pain or improved function without an MRI showing that previously lost cartilage has been completely restored.
Likewise, an imaging change does not always tell the whole story about how someone feels or functions.
Clinical studies therefore look at different outcomes, including pain, mobility, function, imaging findings, adverse effects, and how long any improvement lasts.
The Main Orthobiologic Treatments Patients Commonly Hear About
Several therapies may appear under the regenerative orthopedic medicine label. Their names are sometimes used loosely in advertising, so knowing the basic differences is useful.
Platelet-rich plasma
Platelet-rich plasma, or PRP, is prepared from the patient’s own blood.
Blood is collected and processed, usually through centrifugation, to separate and concentrate platelets within a portion of plasma. The resulting preparation is then placed into the targeted area.
Platelets are well known for their role in blood clotting, but they also contain proteins and signaling molecules involved in the body’s response to injury. AAOS notes that PRP is used in several orthopedic settings, although its effectiveness depends on the condition being treated and research remains active.
PRP should not automatically be described as stem cell therapy. They are biologically different treatments.
Bone marrow aspirate concentrate
Bone marrow aspirate concentrate, often abbreviated BMAC, is produced from bone marrow collected from the patient’s body and processed before use.
Bone marrow contains a mixture of cellular and noncellular components. It is sometimes discussed as a “stem cell treatment,” but that wording can oversimplify what is actually being administered.
Clinical research has examined BMAC for conditions including knee osteoarthritis. A systematic review published in 2025 found improvement from baseline in some studies, while also concluding that superiority over other orthobiologic treatments remained uncertain because results were conflicting.
Another review of randomized trials found that differences between BMAC and other injection options did not consistently reach clinically meaningful thresholds, reinforcing the need for continued research.
Cell, tissue, exosome, and birth-tissue products
Products marketed using terms such as stem cells, exosomes, Wharton’s jelly, umbilical cord tissue, amniotic fluid, or placental tissue require a different level of scrutiny.
FDA continues to warn consumers about unapproved human cell and tissue products being marketed for diseases and orthopedic conditions. The agency states that unapproved products may not have been reviewed for safety, purity, potency, or effectiveness.
A patient’s own PRP procedure should therefore not be assumed to have the same regulatory or biological characteristics as an externally sourced cell or tissue product.
How Does Platelet-Rich Plasma Work?
PRP is one of the most recognizable forms of orthobiologic treatment, yet its mechanism is often described too simply.
The patient’s blood is the starting material
A blood sample is collected and placed in a centrifuge. Centrifugation separates blood components according to their physical properties.
The clinician then uses the desired plasma fraction containing concentrated platelets.
There is no single universal PRP formula. Preparation methods can differ in platelet concentration, white blood cell content, activation methods, volume, processing system, and injection protocol.
That variation is one reason two studies labeled “PRP treatment” may not be evaluating exactly the same biological preparation.
Platelets release biological signals
After reaching the treatment area, activated platelets release signaling proteins and growth factors associated with the body’s response to injury.
Researchers are investigating how these signals may affect inflammatory pathways, tissue cells, blood vessel development, collagen organization, and local healing responses.
The clinical effect depends on much more than platelet concentration alone. The type of injury, disease severity, PRP formulation, injection location, rehabilitation plan, and individual patient characteristics may all affect the result.
PRP does not work equally well for every condition
Evidence differs significantly between orthopedic diagnoses.
Knee osteoarthritis has received considerable research attention. AAOS states that PRP may reduce pain and improve function in patients with symptomatic knee osteoarthritis, but the recommendation remains limited because the available studies are inconsistent and use different preparations and protocols.
Recent research continues to report potentially favorable outcomes in some groups while also identifying substantial differences in study quality and PRP preparation. A 2025 overview of systematic reviews found that the methodological quality of the included reviews was generally low, which is an important reminder that a large number of published papers does not automatically create high certainty.
How Do Bone Marrow Based Orthobiologics Work?
Bone marrow is biologically more complicated than PRP.
It contains many substances involved in blood formation and tissue signaling. When bone marrow aspirate is collected and concentrated, the final preparation contains a mixture of components rather than a single isolated type of regenerative cell.
Collection and processing
Bone marrow is commonly obtained through a needle from an appropriate bone under sterile conditions. The material may then be concentrated before being used.
This requires an additional collection procedure compared with a standard blood draw for PRP.
Because protocols and devices differ, patients should ask exactly how the material is collected, processed, and administered.
The biological goal
BMAC is being studied for its possible effects on inflammatory pathways, tissue signaling, and symptoms associated with conditions such as knee osteoarthritis.
Research does not currently justify assuming that a BMAC injection will rebuild a severely arthritic joint.
AAOS has published a technology overview of concentrated bone marrow aspirate for knee osteoarthritis to summarize the evidence, rather than issuing a blanket recommendation for or against its use.
The difference between “promising treatment under continued study” and “proven joint regeneration” is important for informed consent.
When Might Regenerative Orthopedic Medicine Be Discussed?
There is no universal checklist that makes someone an appropriate candidate for regenerative orthopedic treatment.
The decision begins with a diagnosis.
Pain alone is not enough information because knee pain, for example, could come from osteoarthritis, meniscal injury, tendon disease, referred pain, instability, inflammatory arthritis, fracture, or another cause. Those problems do not necessarily require the same treatment.
Osteoarthritis
Knee osteoarthritis is one of the most frequently studied applications for injectable orthobiologics.
Some patients report improvement after PRP, and research has found potential benefit for pain and function in selected populations. At the same time, AAOS rates its recommendation as limited rather than strong because of inconsistency in the evidence.
Bone marrow based therapies are also being investigated, but current studies have not established that BMAC is clearly superior to other injectable treatments for knee osteoarthritis.
Severity matters. A patient with mild degenerative changes, preserved joint space, and manageable mechanical problems presents a different clinical situation from someone with severe joint destruction and major deformity.
Tendon and ligament problems
PRP has also been studied for tendon injuries and chronic tendinopathy.
The evidence is condition-specific. Findings for one tendon should not automatically be applied to another tendon or ligament.
Before considering an injection, clinicians generally need to understand why the tissue remains symptomatic. An unresolved mechanical problem, incomplete rehabilitation, repeated overload, or a full structural tear may change the treatment plan substantially.
Cartilage, bone, and surgical applications
Orthobiologics are not limited to office injections.
Orthopedic surgeons also use biological materials in certain procedures involving bone healing, cartilage restoration, spinal fusion, tendon repair, ligament surgery, and other musculoskeletal treatments. AAOS describes orthobiologics as having both surgical and nonsurgical applications.
A biologic material used to assist healing during a surgical procedure is a different clinical situation from an injection marketed as a replacement for surgery.
What Happens Before and During Treatment?
A biologic injection should come after appropriate evaluation, not before it.
First comes the diagnosis
A clinician typically starts with the history and physical examination.
Questions may include when symptoms began, where pain occurs, what activities worsen it, whether instability or swelling is present, what treatments have already been tried, and whether an injury caused the problem.
Depending on the condition, X-rays, MRI, ultrasound, or other tests may help clarify the diagnosis.
Imaging should still be interpreted alongside symptoms and examination findings. Treating an MRI finding without determining whether it actually explains the patient’s symptoms can lead to poor treatment decisions.
Candidate selection matters
Two people with the same diagnosis may not be equally suitable for the same procedure.
A clinician may need to consider:
- The exact diagnosis
- Severity of tissue damage
- Previous treatments
- Current medications
- Bleeding or clotting concerns
- Infection risk
- Other medical conditions
- Activity demands
- Mechanical alignment or instability
- Rehabilitation potential
- The patient’s treatment goals
The discussion should also include reasonable alternatives.
The procedure depends on the biologic
PRP generally starts with a blood draw followed by processing and injection.
Bone marrow based procedures involve a separate harvesting step before processing and placement of the final preparation.
Ultrasound, fluoroscopy, or another imaging method may be used for certain procedures when accurate placement matters.
Afterward, temporary soreness can occur. Activity recommendations and rehabilitation vary with the condition, the procedure, and the tissue being treated.
A biologic injection should not be viewed as a substitute for every part of rehabilitation. In many orthopedic problems, progressive loading, mobility work, strength training, and correction of contributing movement problems remain central to recovery.
What Can Patients Realistically Expect?
Perhaps the most important question is also the hardest to answer: will it work?
There is no single success rate that accurately represents regenerative orthopedic medicine.
The term includes different preparations used for different conditions in different patients.
Improvement is not guaranteed
Some studies report improvements in pain and function after particular orthobiologic treatments. Others find smaller differences or no meaningful advantage over comparison treatments.
PRP research in knee osteoarthritis illustrates this problem well.
Some newer studies and reviews report favorable changes in symptoms, yet researchers continue to debate preparation methods, dose, treatment schedules, study quality, and which patients are most likely to benefit.
That is very different from saying PRP “cures arthritis.”
The goal may be symptom control rather than anatomical restoration
For someone with a chronic joint condition, a clinically useful result could mean less pain during walking, greater tolerance for exercise, easier participation in physical therapy, or improved daily function.
Those outcomes can matter even if damaged tissue has not been completely restored.
Patients should therefore ask what outcome the clinician is actually expecting.
Is the goal to reduce symptoms?
Support rehabilitation?
Assist tendon healing?
Delay another intervention?
Improve the biological environment during surgery?
A clear treatment goal makes it easier to judge whether a procedure has been successful.
Why Results Vary So Much Between Patients and Studies
Orthobiologic research is difficult partly because the treatments themselves are not always standardized.
Preparation methods differ
Two PRP products can contain different concentrations and proportions of platelets, plasma, and white blood cells.
Bone marrow preparations can also vary according to the harvesting location, processing method, volume, device, and final cellular composition.
Without standardization, comparing results becomes more difficult.
Orthopedic diagnoses are not uniform
Even “knee osteoarthritis” represents a broad range of disease.
Patients may have different levels of cartilage loss, inflammation, bone changes, meniscal damage, alignment problems, strength deficits, body weight, activity demands, and previous injuries.
A treatment that appears useful in one subgroup may not perform the same way in another.
Research quality matters
A study may report improvement from a patient’s starting point without proving that the treatment caused all of that improvement.
Reliable research often requires appropriate comparison groups, clear eligibility criteria, adequate follow-up, standardized treatment preparation, validated outcome measures, and methods that reduce bias.
Recent research has specifically highlighted methodological weaknesses across parts of the PRP literature, which helps explain why professional recommendations remain more cautious than some marketing language suggests.
Risks and Limitations Should Be Part of the Conversation
“Natural” does not mean risk-free.
Even a product prepared from a patient’s own blood requires needle placement and medical judgment.
Possible risks vary by procedure but can include temporary pain, swelling, bleeding, infection, reaction at the treatment site, and complications related to tissue harvesting or injection.
For a bone marrow procedure, the harvesting site introduces considerations that are not present with a simple blood draw.
The risks can be different again when donor-derived, commercially processed, manipulated, or unapproved cell and tissue products are involved.
Delaying appropriate treatment is also a potential harm
Risk is not limited to what happens during the injection.
Imagine someone has a structural problem that requires a different form of treatment but spends months repeatedly receiving biologic injections because they were told surgery would never be necessary.
Even if the injections themselves cause no direct complication, delaying appropriate evaluation may prolong disability or allow the underlying problem to progress.
A trustworthy treatment discussion includes both the potential benefits and the possibility that another approach may be more appropriate.
What Does the FDA Say About Regenerative Medicine Products?
Regulatory language surrounding regenerative medicine can be confusing, especially when clinics use terms such as “FDA registered,” “FDA compliant,” or “FDA cleared.”
Those phrases should not automatically be interpreted as proof that a particular biological product is FDA approved to treat an orthopedic condition.
FDA states that regenerative medicine products, including many stem cell and exosome products, are subject to federal regulation. The agency has repeatedly warned about unapproved products marketed for orthopedic conditions such as osteoarthritis, tendon problems, back pain, knee pain, hip pain, and shoulder pain.
FDA also issued a 2026 warning concerning risks associated with unapproved products made from human cells or tissues and continues to advise consumers to be cautious when products have not undergone the required review.
“Registered” does not mean “approved”
A company appearing in an FDA database or a study being listed on ClinicalTrials.gov does not by itself prove that a treatment is FDA approved or legally marketed for a particular condition.
FDA specifically warns consumers against assuming that registration or a clinical trial listing establishes approval.
Patients considering a cell or tissue based procedure should ask the treating clinician for the exact product name and its regulatory status.
Be cautious with sweeping promises
Claims deserve additional scrutiny when a single product is advertised as treating a long list of unrelated problems.
Orthopedic arthritis, neurological disease, heart disease, autoimmune conditions, chronic pain, and anti-aging concerns involve very different biological processes.
A product promoted as a solution for nearly all of them should prompt questions about the supporting evidence and regulatory status.
Questions Worth Asking Before Choosing a Regenerative Orthopedic Treatment
A productive consultation should give a patient enough information to make an informed decision, including reasons not to proceed.
Useful questions include:
- What is my exact diagnosis?
- What tissue is causing my symptoms?
- Why are you recommending this treatment for my condition?
- What exactly will be injected or implanted?
- Does the material come from my own body or another source?
- How is it processed?
- Is this PRP, bone marrow aspirate concentrate, a cell product, or something else?
- What evidence supports its use for my specific diagnosis?
- What are the realistic treatment goals?
- What are the risks?
- What happens if it does not work?
- What other treatments could I consider?
- Will physical therapy or rehabilitation still be necessary?
- Could waiting affect my condition?
- What is the FDA regulatory status of the product being offered?
- Is the procedure generally covered by insurance, or will I be responsible for the cost?
A clinician should be able to answer these questions without relying on vague promises about “healing naturally.”
Finding the Right Place for Regenerative Medicine in Orthopedic Care
Regenerative orthopedic medicine occupies an interesting position between established orthopedic care and an active area of medical research.
Some orthobiologic approaches, particularly PRP for certain musculoskeletal conditions, have accumulated meaningful clinical research. At the same time, evidence remains inconsistent across diagnoses, preparations, and patient populations. Bone marrow based procedures continue to be studied, and many commercially marketed cell, tissue, and exosome products require much greater regulatory and scientific caution.
The most useful question is therefore not simply, “Does regenerative medicine work?”
A better question is:
Does this specific treatment have reasonable evidence for this specific diagnosis, in this particular patient, at this stage of the condition?
That question requires a proper orthopedic diagnosis, an understanding of the available evidence, realistic expectations, and a discussion of alternatives.
For some patients, an orthobiologic procedure may become one part of a broader treatment plan. For others, physical therapy, medication, lifestyle changes, conventional injections, or surgery may make more sense.
Regenerative orthopedic medicine is most useful when it is treated as medicine rather than marketing. The treatment should begin with the problem that needs to be solved, not with an injection looking for a reason to be used.
This article is intended for general educational purposes and does not replace evaluation, diagnosis, or treatment recommendations from a qualified healthcare professional.